NCT01843374 2026-03-05
Tremelimumab
MedImmune LLC
Phase 2 Active not recruiting
Clinical Trials
18 trialsNCT05136677 2026-01-23
CheckMate 6DW
Bristol-Myers Squibb
Phase 2 Completed
NCT04914897 2025-10-02
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
Sanofi
Phase 2 Terminated
NCT05563272 2025-07-10
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 2 Terminated
NCT01265433 2024-10-09
Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy
Sellas Life Sciences Group
Phase 2 Completed
NCT05425576 2024-03-15
OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition
Mateon Therapeutics
Phase 2 Not yet recruiting
NCT02004028 2024-02-20
Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants
Verastem, Inc.
Phase 2 Terminated
NCT00738582 2022-09-22
Amatuximab
Morphotek
Phase 2 Completed
NCT04013334 2022-06-16
MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma
Momotaro-Gene Inc.
Phase 2 Unknown
NCT02357147 2020-03-17
ARTEMIS
Morphotek
Phase 2 Terminated
NCT03175172 2019-04-04
Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)
Aduro Biotech, Inc.
Phase 2 Terminated
NCT00484276 2019-01-16
NGR010
AGC Biologics S.p.A.
Phase 2 Completed
NCT01358084 2019-01-15
NGR019
AGC Biologics S.p.A.
Phase 2 Completed
NCT02397928 2018-09-25
Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)
NovoCure Ltd.
Phase 2 Completed
NCT01870609 2017-01-30
COMMAND
Verastem, Inc.
Phase 2 Terminated
NCT00027508 2015-02-24
Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma
PharmaMar
Phase 2 Terminated
NCT00787410 2012-06-06
An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma
AstraZeneca
Phase 2 Completed
NCT00386815 2007-04-11
Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma
Eli Lilly and Company
Phase 2 Completed